2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population
Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.Peer-Reviewed Original ResearchConceptsGenomic dataEstimates of mutation ratesSomatic missense mutationsGenomic informationPopulation-level estimatesCancer patient populationMissense mutationsNon-epidemiologicallyCancer patientsMutation ratePathogenic mutationsCysteine residuesCancer epidemiologyMutation-specificMutation abundanceDrug targetsMutationsIntegrates epidemiologyAbundancePatient populationEpidemiologyGenomePopulationTargeted therapyResidues
2024
Cancer research is not correlated with driver gene mutation burdens
Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, DOI: 10.1016/j.medj.2024.05.013.Peer-Reviewed Original ResearchCancer patient populationCancer researchCancer research effortsResearch allocation decisionsNational InstitutePatient populationResearch fundingBurdenBurden of mutationsFunding decisionsCancerGenetic driversGene mutation burdenFunding amountFundingGenetic drivers of cancerAllocation decisionsCancer-associated genesEpidemiologyDrivers of cancerMutational burdenBaselineEffortsFactorsBalance of priorities
2022
How often is each gene mutated within the cancer patient population?
Mendiratta G, Jones M, Stites E. How often is each gene mutated within the cancer patient population? Molecular & Cellular Oncology 2022, 9: 2065176. PMID: 35529901, PMCID: PMC9067461, DOI: 10.1080/23723556.2022.2065176.Peer-Reviewed Original Research
2020
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption
Dinan MA, Wilson LE, Reed SD, Griggs JJ, Norton EC. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. Clinical Breast Cancer 2020, 20: 487-494.e1. PMID: 32653473, DOI: 10.1016/j.clbc.2020.05.010.Peer-Reviewed Original Research
2019
Regionalization of esophagectomy: where are we now?
Clark JM, Boffa DJ, Meguid RA, Brown LM, Cooke DT. Regionalization of esophagectomy: where are we now? Journal Of Thoracic Disease 2019, 1: s1633-s1642. PMID: 31489231, PMCID: PMC6702400, DOI: 10.21037/jtd.2019.07.88.Peer-Reviewed Original Research
2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbiditiesManagement outcomes of diverticulitis and colitis in patients with active cancer
Horwood C, Wisler J, Byrd S, Woodling K, Schneider E, Rushing A. Management outcomes of diverticulitis and colitis in patients with active cancer. Surgery 2018, 164: 350-353. PMID: 29801733, DOI: 10.1016/j.surg.2018.03.010.Peer-Reviewed Original ResearchConceptsActive cancer diagnosisColonic emergenciesActive cancerNonoperative managementIntensive care unit admissionEmergent general surgeryCare unit admissionPreoperative risk factorsCancer diagnosisNon-operative managementCancer patient populationIntensive care unitNonoperative groupNonoperative patientsUnit admissionPostoperative complicationsCare unitColonic pathologyOperative groupSurgery consultOperative managementPatient populationCancer DatabaseRisk factorsGeneral surgery
2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis R. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal Of The National Cancer Institute 2015, 107: djv256. PMID: 26376684, PMCID: PMC4681582, DOI: 10.1093/jnci/djv256.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorBone NeoplasmsBreast NeoplasmsCell Line, TumorDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticHeterograftsHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMiceMice, Inbred BALB COdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsProto-Oncogene Proteins c-mafUp-RegulationConceptsBreast cancer bone metastasisCopy number aberrationsCancer bone metastasisBone metastasesRisk of bone metastasisAssociated with bone metastasisBreast cancer cells in vivoPrimary breast tumorsBreast cancer patient populationCancer cells in vivoMetastasis to boneClinical follow-upBreast cancer cellsAssociated with riskCells in vivoCancer patient populationBone relapseCause-specific hazard modelBreast tumorsFollow-upMAF overexpressionMetastasisPatient populationProtein overexpressionCancer cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply